A rise in FSH levels is most widely recognized hallmark of reduction in the OR.5 It may not be the best option as it suffers inter and intra cyclic fluctuations.6 FSH production is further deranged in patients receiving oral contraceptive pills, in polycystic ovarian syndrome (PCOS) and pituitary tumors.7 Similarly, AFC is assessed for estimation of dosage and in predicting response to stimulation but operators’ variability, mechanical consistency and previous history of ovarian surgery are its main limitations. The gene discussed is BRD2; the disease is pituitary tumor.